Meta-analyses and multi-omics surveys link m6A regulator abundance to CTLA-4 expression patterns across cancers, and Treg- and DC-centric m6A programs plausibly alter the outcomes of CTLA-4 blockade via effects on antigen presentation and Treg stability. This evidence concerns the gene CTLA4 and cancer.